NEOG vs. QDEL, CLDX, NTLA, MYGN, LNTH, CERT, HIMS, EVO, SMMT, and MOR
Should you be buying Neogen stock or one of its competitors? The main competitors of Neogen include QuidelOrtho (QDEL), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Lantheus (LNTH), Certara (CERT), Hims & Hers Health (HIMS), Evotec (EVO), Summit Therapeutics (SMMT), and MorphoSys (MOR). These companies are all part of the "medical" sector.
Neogen (NASDAQ:NEOG) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Neogen has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.
96.7% of Neogen shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 0.7% of Neogen shares are held by company insiders. Comparatively, 1.0% of QuidelOrtho shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Neogen has a net margin of 0.17% compared to QuidelOrtho's net margin of -0.34%. QuidelOrtho's return on equity of 5.54% beat Neogen's return on equity.
QuidelOrtho received 109 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.23% of users gave QuidelOrtho an outperform vote while only 57.19% of users gave Neogen an outperform vote.
Neogen presently has a consensus price target of $22.50, indicating a potential upside of 86.57%. QuidelOrtho has a consensus price target of $61.60, indicating a potential upside of 53.85%. Given Neogen's stronger consensus rating and higher possible upside, equities analysts clearly believe Neogen is more favorable than QuidelOrtho.
In the previous week, QuidelOrtho had 20 more articles in the media than Neogen. MarketBeat recorded 26 mentions for QuidelOrtho and 6 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.11 beat Neogen's score of -0.02 indicating that QuidelOrtho is being referred to more favorably in the news media.
Summary
QuidelOrtho beats Neogen on 11 of the 18 factors compared between the two stocks.
Get Neogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
